A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
BACKGROUND: CRTH2 is a G-protein-coupled receptor that mediates the activation of Th2 lymphocytes, eosinophils and basophils in response to prostaglandin D(2) and may be involved in the pathogenesis of airway inflammation and dysfunction in asthma. OBJECTIVE: To evaluate the effects of a potent and...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797068836757831680 |
|---|---|
| author | Barnes, N Pavord, I Chuchalin, A Bell, J Hunter, M Lewis, T Parker, D Payton, M Collins, L Pettipher, R Steiner, J Perkins, C |
| author_facet | Barnes, N Pavord, I Chuchalin, A Bell, J Hunter, M Lewis, T Parker, D Payton, M Collins, L Pettipher, R Steiner, J Perkins, C |
| author_sort | Barnes, N |
| collection | OXFORD |
| description | BACKGROUND: CRTH2 is a G-protein-coupled receptor that mediates the activation of Th2 lymphocytes, eosinophils and basophils in response to prostaglandin D(2) and may be involved in the pathogenesis of airway inflammation and dysfunction in asthma. OBJECTIVE: To evaluate the effects of a potent and selective CRTH2 antagonist, OC000459, on the lung function, symptoms and eosinophilic airway inflammation in a double-blind, parallel group trial in steroid-free subjects with moderate persistent asthma. METHODS: Adult subjects were randomized to oral OC000459 200 mg twice daily (N=65) or a placebo (N=67) for 28 days. The primary end-point was the change from baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV(1) ); eosinophilic airway inflammation was assessed by induced sputum differential eosinophil count. The trial was registered on the clinicaltrials.gov database (Identifier NCT01057927). RESULTS: Data were analysed for both the Full Analysis (FA) population and the Per Protocol (PP) population (55 treated with OC000459 and 52 with placebo), which excluded non-compliant subjects. In the FA population, the mean change in FEV(1) was 7.1% on OC000459 compared with 4.3% on placebo (not significant); in the PP population, the mean changes were 9.2% and 1.8%, respectively (P=0.037). Improvement in quality of life was apparent in both FA and PP populations [difference from the placebo in AQLQ(S) total score of 0.29, P=0.0113 and 0.37, P=0.0022, respectively]. OC000459 also improved the night-time symptom scores (mean reduction of 0.36 vs. 0.11, P=0.008, FA population; 0.37 vs. 0.12, P=0.022, PP population). The geometric mean sputum eosinophil count reduced from 2.1% to 0.7% (P=0.03) after OC000459, but this effect was not significant when compared with the change on placebo (P=0.37). Adverse events on OC000459 were comparable to those on placebo; respiratory infections were notably less common during OC000459 than the placebo treatment. CONCLUSION AND CLINICAL RELEVANCE: This study provides the first clinical evidence that CRTH2 receptors contribute to airflow limitation, symptoms and eosinophilic airway inflammation in asthma. OC000459 shows promise as a novel oral treatment for asthma and related disorders. |
| first_indexed | 2024-03-06T22:15:47Z |
| format | Journal article |
| id | oxford-uuid:5357d100-375f-402d-9be6-e21baf43a685 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:15:47Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:5357d100-375f-402d-9be6-e21baf43a6852022-03-26T16:31:03ZA randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5357d100-375f-402d-9be6-e21baf43a685EnglishSymplectic Elements at Oxford2012Barnes, NPavord, IChuchalin, ABell, JHunter, MLewis, TParker, DPayton, MCollins, LPettipher, RSteiner, JPerkins, CBACKGROUND: CRTH2 is a G-protein-coupled receptor that mediates the activation of Th2 lymphocytes, eosinophils and basophils in response to prostaglandin D(2) and may be involved in the pathogenesis of airway inflammation and dysfunction in asthma. OBJECTIVE: To evaluate the effects of a potent and selective CRTH2 antagonist, OC000459, on the lung function, symptoms and eosinophilic airway inflammation in a double-blind, parallel group trial in steroid-free subjects with moderate persistent asthma. METHODS: Adult subjects were randomized to oral OC000459 200 mg twice daily (N=65) or a placebo (N=67) for 28 days. The primary end-point was the change from baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV(1) ); eosinophilic airway inflammation was assessed by induced sputum differential eosinophil count. The trial was registered on the clinicaltrials.gov database (Identifier NCT01057927). RESULTS: Data were analysed for both the Full Analysis (FA) population and the Per Protocol (PP) population (55 treated with OC000459 and 52 with placebo), which excluded non-compliant subjects. In the FA population, the mean change in FEV(1) was 7.1% on OC000459 compared with 4.3% on placebo (not significant); in the PP population, the mean changes were 9.2% and 1.8%, respectively (P=0.037). Improvement in quality of life was apparent in both FA and PP populations [difference from the placebo in AQLQ(S) total score of 0.29, P=0.0113 and 0.37, P=0.0022, respectively]. OC000459 also improved the night-time symptom scores (mean reduction of 0.36 vs. 0.11, P=0.008, FA population; 0.37 vs. 0.12, P=0.022, PP population). The geometric mean sputum eosinophil count reduced from 2.1% to 0.7% (P=0.03) after OC000459, but this effect was not significant when compared with the change on placebo (P=0.37). Adverse events on OC000459 were comparable to those on placebo; respiratory infections were notably less common during OC000459 than the placebo treatment. CONCLUSION AND CLINICAL RELEVANCE: This study provides the first clinical evidence that CRTH2 receptors contribute to airflow limitation, symptoms and eosinophilic airway inflammation in asthma. OC000459 shows promise as a novel oral treatment for asthma and related disorders. |
| spellingShingle | Barnes, N Pavord, I Chuchalin, A Bell, J Hunter, M Lewis, T Parker, D Payton, M Collins, L Pettipher, R Steiner, J Perkins, C A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title_full | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title_fullStr | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title_full_unstemmed | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title_short | A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. |
| title_sort | randomized double blind placebo controlled study of the crth2 antagonist oc000459 in moderate persistent asthma |
| work_keys_str_mv | AT barnesn arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT pavordi arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT chuchalina arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT bellj arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT hunterm arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT lewist arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT parkerd arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT paytonm arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT collinsl arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT pettipherr arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT steinerj arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT perkinsc arandomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT barnesn randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT pavordi randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT chuchalina randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT bellj randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT hunterm randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT lewist randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT parkerd randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT paytonm randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT collinsl randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT pettipherr randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT steinerj randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma AT perkinsc randomizeddoubleblindplacebocontrolledstudyofthecrth2antagonistoc000459inmoderatepersistentasthma |